Next Article in Journal
Detecting Retroviral Sequences in Chronic Fatigue Syndrome
Next Article in Special Issue
Development of ST-246® for Treatment of Poxvirus Infections
Previous Article in Journal
Poxvirus Exploitation of the Ubiquitin-Proteasome System
Previous Article in Special Issue
Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents
Review

Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections

by 1 and 1,2,*
1
Division of Infectious Diseases, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
2
Infectious Diseases Section, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Viruses 2010, 2(10), 2381-2403; https://doi.org/10.3390/v2102381
Received: 19 September 2010 / Revised: 9 October 2010 / Accepted: 13 October 2010 / Published: 20 October 2010
(This article belongs to the Special Issue Antivirals Against Poxviruses)
Despite the eradication of smallpox several decades ago, variola and monkeypox viruses still have the potential to become significant threats to public health. The current licensed live vaccinia virus-based smallpox vaccine is extremely effective as a prophylactic vaccine to prevent orthopoxvirus infections, but because of safety issues, it is no longer given as a routine vaccine to the general population. In the event of serious human orthopoxvirus infections, it is important to have treatments available for individual patients as well as their close contacts. The smallpox vaccine and vaccinia immune globulin (VIG) were used in the past as therapeutics for patients exposed to smallpox. VIG was also used in patients who were at high risk of developing complications from smallpox vaccination. Thus post-exposure vaccination and VIG treatments may again become important therapeutic modalities. This paper summarizes some of the historic use of the smallpox vaccine and immunoglobulins in the post-exposure setting in humans and reviews in detail the newer animal studies that address the use of therapeutic vaccines and immunoglobulins in orthopoxvirus infections as well as the development of new therapeutic monoclonal antibodies.
Keywords: orthopoxvirus; variola virus; vaccinia virus; monkeypox virus; post-exposure vaccination; Dryvax; Lister; modified vaccinia Ankara (MVA); vaccinia immune globulin (VIG); monoclonal antibodies orthopoxvirus; variola virus; vaccinia virus; monkeypox virus; post-exposure vaccination; Dryvax; Lister; modified vaccinia Ankara (MVA); vaccinia immune globulin (VIG); monoclonal antibodies
MDPI and ACS Style

Xiao, Y.; Isaacs, S.N. Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections. Viruses 2010, 2, 2381-2403. https://doi.org/10.3390/v2102381

AMA Style

Xiao Y, Isaacs SN. Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections. Viruses. 2010; 2(10):2381-2403. https://doi.org/10.3390/v2102381

Chicago/Turabian Style

Xiao, Yuhong; Isaacs, Stuart N. 2010. "Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections" Viruses 2, no. 10: 2381-2403. https://doi.org/10.3390/v2102381

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop